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Abstract
The high incidence of Campylobacter jejuni-associated diarrhoea, the increase in the frequency of drug resistance, and the 
correlation between infection and Guillain-Barré syndrome, has heightened the need to develop effective anti-Campylobacter
vaccines. Due to the risk of auto-immunity, vaccinations using whole-cells or attenuated cells are not clinical candidates. Subunit 
vaccines are viable alternatives and have been shown to be effective against other enteric pathogens. This research tested the
efficacy of the catalase (KatA) from C. jejuni as a potential vaccine candidate against the pathogen. The protein was found to be 
immunogenic following an intramuscular murine immunization. A balanced IgG1/IgG2a response was generated when KatA was 
co-administered with monophosphoryl lipid A and alum. The antibodies elicited reduced the adhesion and invasion of C. jejuni to 
human epithelial cells (IECs) in vitro. The next phase of testing will be in combination with a proteoliposome (PL) derived from 
the outer membrane of V. cholerae. PL nano-YHVLFOHVZHUHJHQHUDWHGZLWKDQDYHUDJHVL]HRI§QP and had a zeta potential of  
§-40 mV. 
© 2015 The Authors. Published by Elsevier B.V.
Selection and peer-review under responsibility of the 8th Vaccine Conference Organizing Committee.
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1. Background
Every year, diarrhoeal diseases claim the lives of over 5 million children living in conditions where the lack of 
food and water sanitation fosters the transmission of enteric pathogens [1]. Campylobacter jejuni is the most 
frequently reported cause of bacterial gastroenteritis in humans [2] and the second leading cause of traveller’s 
diarrhoea following Escherichia coli [3]. The high incidence of C. jejuni infections and increasing antibiotic 
resistance [4] has prompted the development of vaccines against this pathogen. The recent association of C. jejuni
© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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infections and Guillain-Barré syndrome (GBS) [5] has created an unusual dilemma by eliminating the possibility of 
developing a whole-killed or attenuated vaccine. GBS is a neurological disease characterized by ascending paralysis 
that can lead to respiratory muscle compromise and even death [6]. It is the leading cause of acute neuromuscular 
paralysis in the developed world and is believed to be the result of a post-infection autoimmune response [6]. The 
outer membrane of C. jejuni contains lipopolysaccharide (LPS) and lipooligosaccharide (LOS) that closely resemble 
human gangliosides on the myelin sheath of neurons triggering antibody-mediated demyelination [7].
The catalase A (KatA) protein is a homotetrameric protein approximately 55 kDa is size. It has been suggested to 
be an excellent vaccine candidate against enteric bacteria such as C. jejuni [8]. Palyada et al. (2009) confirmed the 
necessity of the KatA protein for host colonization in vivo as KatA deficient C. jejuni mutants were unable to 
colonize the cecum of baby chicks [9]. The antigenicity of the KatA protein, however, is yet to be tested and the 
functionality of the antibodies verified. 
In the effort to develop a novel C. jejuni vaccination strategy, a proteoliposome delivery system will be tested. 
The proteoliposome (PL) is a new concept and has recently been employed as highly effective vaccine technology
[10,11]. PLs are nanoparticles derived from the outer membranes of bacteria and contain numerous pathogen-
associated molecular patterns (PAMPs) that effectively stimulate the innate immune system [12]. Recent research has
demonstrated the ability of PLs to stimulate enhanced mucosal immunity to a secondary unrelated antigen co-
administered with the PL[10]. This preliminary work involved the production and characterization of PLs in house 
from Vibrio cholerae. In the second phase of this research, the PL will be tested with KatA in a mucosal vaccine 
administration.
2. Materials and Methods
KatA Protein
Overexpression of KatA was performed in E. coli BL21 cells using the protein expression vector pGST and 
purification was performed as described previously [13]. In brief, E. coli cells were pelleted and resuspended in 100
mM NaCl,10 mM Tris pH 7.3 buffer containing protease inhibitor (Roche, Mississauga, Canada). The cell 
membranes were disrupted via sonication and debris was removed by centrifugation at 13,000 rpm for 15 min. The 
cell lysate containing the GST-KatA fusion protein was then purifed using glutathione sepharose 4B resin (GE 
Healthcare, Baie D’Urfe, Canada). Clevage of the GST tag from KatA was performed on the resin with the addition 
of TEV protease and gentle shaking overnight. The KatA protein was washed from the resin using 100 mM NaCl, 
20 mM Tris pH 7.3 and concentrated using a 30 kDa cut-off centrifugal filter (EMD Millipore, MA, USA). The 
concentrated KatA protein was further purified by sized exclusion chromatography using the AKTA fast protein 
liquid chromatography (FPLC) system equipped with a Superdex-200 column (GE Healthcare). 
Immunization
The vaccine was administered intramuscularly at time 0, 3 and 6 weeks to female BALB/c mice (Charles River 
Laboratories, Sherbrooke, Canada). Four mice were housed per cage and food and water was provided ad libitum.
Eight mice were in each immunization group. All experiments were conducted according to the Guidelines for the 
Care and Use of Laboratory Animals and was approved by the Animal Care Committee of Laurentian University 
(Sudbury, Canada). Adjuvants, added where required included alum (Invivogen, San Diego, CA) and 
monophosphoryl lipid A (MPL, Invivogen) (Table 1).
Table 1. Vaccine formulations administered via intramuscular injection to mice.
Group Vaccine Formulations
A PBS
B 5 μg KatA
C 5 μg KatA + 100 μg Alum
D 5 μg KatA + 5 μg MPL
E 5 μg KatA + 100 μg Alum + 5 μg MPL
F 108 inactivated/killed C. jejuni in PBS
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ELISA
Antibody levels and isotypes were examined via enzyme-linked immunosorbent assay (ELISA)  using plates 
coated with purified recombinant KatA protein LQFXEDWHGRYHUQLJKWDWÛ&'LOXWHGPRXVHVHUXP (collected at week 
7) ZDVDGGHGDQGLQFXEDWHGRYHUQLJKWDWÛ&3ODWHVZHUHZDVKed with TBST and biotinylated goat-anti-mouse IgG, 
IgG1 and IgG2a antibodies (diluted 1:10000 in TBST) were added for 1 h at room temperature. Alkaline 
phosphatase conjugated with streptavidin (diluted 1:5000 in TBST) was added (1 h incubation, room temperature). 
Plates were washed in ddH2O and PNPP (diluted 1:100 in TBST) was added and developed for 5-15 min before 
absorbance was read at 405 nm using a Synergy H4 microplate reader (Biotek).
Adhesion/Invasion Assay
C. jejuni NCTC11168 was grown in Mueller-Hinton (MH) broth for 24-36 hours (log phase growth) under 
microaerophilic conditions (5% O2, 10% CO2, 85% N2) DWÛ&. 106 Caco-2 cells (ATCC) were seeded in 24 well 
tissue culture plates for 48 h. Serum from the immunized mice was diluted in PBS (1:10, 1:50; 1:100) and incubated 
with the bacteria for 1 hour at 37°C. The mixture was then incubated with the Caco-2 monolayer for 3 hours at 37°C 
and 5% CO2.
In the adhesion assay, cells were lysed with 0.1% Triton X-100, whereas invasion assays had cells incubating for an 
additional 2 h in 480 μg/ml of gentamicin to kill adhered bacteria. The number of viable bacteria released following 
the lysis step was assessed by plating a 50-fold dilution on MH agar and counting the number of CFU after a 48-h
LQFXEDWLRQDWÛ&XQGHUPLFURDHURSKLOLFFRQGLWLRQV
Proteoliposomes
Vibrio cholerae (strain 01, National Microbiology Laboratory, Winnipeg, Canada) was grown in Tryptone soy 
broth (~ 18 h) at 37 Ԩ in an orbital shaker. Outer membrane proteins were extracted using a mild detergent 10% 
sodium deoxycholate, 50mM Tris, 10mM EDTA pH 8.5 KÛ&ZLWKFRQVWDQWDJLWDWLRQ&HOO debris was 
removed via centrifugation at 30[JIRUPLQXWHVDWÛ&7KHVXSHUQDWDQWWKHQXQGHUZHQWultracentrifugation
(85,000xg, KÛ&. The pellet was re-suspended in buffer containing 50mM Tris,10mM EDTA, pH 8.5 and 
filtered through a 0.45 μm and then 0.2 μm sterile Minisart syringe filter (Sartorius, USA). This method was derived 
from work published by Pérez et al. (2009) [14].The PL particle size distribution was analzyed using a Zetasizer NS 
(Malvern Instruments, UK). The protein size distribution was also examined via SDS-PAGE and revealed the 
presence of more than 15 unique proteins (data not shown). PLs were visualized using scanning electron microscopy 
using a JSEM 6400 instrument (JEOL Ltd, UK). Briefly, approximately 1 μl of sample was spotted on a microscope
slide with conductive copper tape and permitted to air dry. Images were recorded operating at 20 kV using INCA 
Energy software (High Wycombe, UK). Images were taken at 18-20,000x magnification. 
3. Results
Anti-KatA antibodies were elicited following the immunization. Sera from mice immunized with KatA alone had 
mean anti-KatA IgG end point titers of 1.9x106. Mean ELISA titers were comparable at 3.9x106 and 3.8x106 in mice 
immunized with KatA in conjunction with alum and MPL respectively (p < 0.05 compared to the PBS group). Mice 
immunized with formalin inactivated C. jejuni had mean end point ELISA titers of 2.5x105. The highest titers 
(5.6x106) were observed in sera from mice immunized with KatA and a combination of both adjuvants 
(alum+MPL), which was significant (p < 0.05) compared to titers induced by KatA alone, PBS, and killed bacteria 
(Figure 1). The sera from mice immunized with KatA alone primarily had antibody mediated immune responses 
reflected by the Th2 bias (Figure 3). Mice immunized with benchmark vaccine (formalin inactivated C. jejuni) also 
had a Th2 bias suggestive of a predominant antibody mediated response. Balanced Th1 and Th2 responses were 
observed in mice that received KatA in conjunction with both alum and MPL. (Figure 2)
The resulting antibodies were effective in reducing the rates of C. jejuni adhesion and invasion of IECs in vitro. In
the adhesion assay, (Figure 3A) (1:10  serum dilution) there was a 54.4 ± 2.4% CFU decrease in serum raised 
against whole bacteria, 43.5 ± 1.3% with KatA and alum/MPL, and 36.6 ± 2.5% decrease in CFU from serum raised 
against KatA alone (p < 0.05) when normalized against serum from mice immunized with PBS. In the invasion 
assay, (Figure 3B) (1:10 dilution) there were no significant differences between the percent CFU decrease using 
serum from whole cell bacteria 53.5 ± 3.1%, KatA/alum/MPL 42.7 ± 4.9%, and KatA alone 40.4 ± 2.4%.
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PLs were successfully visualized using scanning electronmicroscopy (Fig. 4A). PLs were determined to have an 
average particle size distribution of §70 nm (Fig. 4B) with three unique populations. 76.5% of the distribution fell 
within the range of 65-150 nm; 16.5% in the 5-25 nm range, and 6.9% > 1 μm. The zeta potential was §-40 mV 
refelcting moderate stability (data not shown).
Figure 1. Total IgG in mouse serum one week after three intramuscular immunizations. Values represent the 
mean endpoint titers within each group of mice (n = 8). Errors bars shown represent the standard error within each 
mouse group. An asterisk indicates significant differences between groups, p < 0.05.
Figure 2.The addition of alum or MPL to KatA induces a balanced IgG2a/IgG1 ratio. Mouse serum was 
evaluated for IgG1 and IgG2a subtypes and measured by OD405 by KatA-specific ELISA. OD is indicated for each 
mouse (n=8); line in each group represents the mean OD +/- SE.
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Figure 3.The effect of serum antibodies in preventing the (A) adhesion and (B) invasion of C. jejuni to human 
epithelial cells (Caco-2) in vitro. A one-way ANOVA was performed with a Tukey’s multiple comparison test to 
assess for statistically significant differences.
Figure 4. PL visualization and particle size distribution analysis. (A) Scanning electron micrograph of V.
cholerae PLs at 19,000X; Scale bar = 1.0 μm. (B) Particle size distribution profile of PLs illustrates the multimodal 
distribution of particle sizes.
4. Conclusion
The KatA protein has demonstrated immunogenicity in the murine model through the generation of KatA specific 
antibodies. In addition, the antibodies were determined to reduce the rate of C. jejuni adhesion and invasion of 
human IECs. The data presented here supports the candidacy of the KatA protein as a vaccine antigen in the effort to 
design a subunit vaccine against C. jejuni infections. Further investigation is warranted and the next phase of testing 
will involve the mucosal delivery of the protein in combination with the mucosal adjuvants. The proteoliposome,
derived from the outer membrane of the enteric pathogen V. cholerae, may be a suitable adjuvant for the generation 
of high levels of protective antibodies. Future studies will evaluate the effectiveness of this combination and the 
protection generated against C. jejuni infections in vivo.
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